{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-062387","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.142618+00:00","generated_at":"2026-06-01T12:26:33.125131+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"FDA removes partial clinical hold on Larimar's nomlabofusp for Friedreich's Ataxia","bullets":["FDA cleared Phase 2 data review; nomlabofusp generally well-tolerated with dose-dependent frataxin increases.","OLE study continues at 25 mg; dose escalation to 50 mg planned after further frataxin PD characterization.","Interim OLE data expected Q4 2024; BLA submission targeted for 2H 2025.","In 50 mg cohort, all evaluable patients achieved skin frataxin >33% of healthy volunteer average at Day 14."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-062387","json":"https://secwatch.observer/filing/0000950170-24-062387.json","markdown":"https://secwatch.observer/filing/0000950170-24-062387.md","text":"https://secwatch.observer/filing/0000950170-24-062387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/0000950170-24-062387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024062387/lrmr-20240520.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T12:26:33.125131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}